Equities research analysts at Jefferies Group assumed coverage on shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) in a research note issued to investors on Friday. The firm set a “buy” rating and a $12.00 price target on the stock. Jefferies Group’s price objective indicates a potential upside of 110.53% from the company’s current price.

A number of other brokerages have also recently issued reports on DMTX. Canaccord Genuity restated a “buy” rating and set a $20.00 target price on shares of Dimension Therapeutics in a report on Thursday, November 10th. Zacks Investment Research cut Dimension Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 10th. Finally, Chardan Capital set a $10.00 target price on Dimension Therapeutics and gave the stock a “hold” rating in a report on Sunday, August 21st. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $15.21.

Analyst Recommendations for Dimension Therapeutics (NASDAQ:DMTX)

Shares of Dimension Therapeutics (NASDAQ:DMTX) opened at 5.70 on Friday. Dimension Therapeutics has a 52 week low of $4.00 and a 52 week high of $15.55. The company’s market cap is $142.75 million. The company has a 50 day moving average price of $6.44 and a 200 day moving average price of $7.07.

Several large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in Dimension Therapeutics by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 239,000 shares of the company’s stock worth $1,871,000 after buying an additional 80,200 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Dimension Therapeutics by 113.2% in the second quarter. California State Teachers Retirement System now owns 25,634 shares of the company’s stock worth $154,000 after buying an additional 13,610 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Dimension Therapeutics by 180.8% in the second quarter. Bank of New York Mellon Corp now owns 28,743 shares of the company’s stock worth $173,000 after buying an additional 18,506 shares in the last quarter. Bridgeway Capital Management Inc. purchased a new stake in shares of Dimension Therapeutics during the second quarter worth about $128,000. Finally, State Street Corp raised its stake in shares of Dimension Therapeutics by 69.0% in the second quarter. State Street Corp now owns 110,725 shares of the company’s stock worth $665,000 after buying an additional 45,200 shares in the last quarter. 85.52% of the stock is currently owned by institutional investors.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Receive News & Stock Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related stocks with our FREE daily email newsletter.